Literature DB >> 8968079

Asbestos causes stimulation of the extracellular signal-regulated kinase 1 mitogen-activated protein kinase cascade after phosphorylation of the epidermal growth factor receptor.

C L Zanella1, J Posada, T R Tritton, B T Mossman.   

Abstract

Asbestos fibers are human carcinogens with undefined mechanisms of action. In studies here, we examined signal transduction events induced by asbestos in target cells of mesothelioma and potential cell surface origins for these cascades. Asbestos fibers, but not their nonfibrous analogues, induced protracted phosphorylation of the mitogen-activated protein (MAP) kinases and extracellular signal-regulated kinases (ERK) 1 and 2, and increased kinase activity of ERK2. ERK1 and ERK2 phosphorylation and activity were initiated by addition of exogenous epidermal growth factor (EGF) and transforming growth factor-alpha, but not by isoforms of platelet-derived growth factor or insulin-like growth factor-1 in mesothelial cells. MAP kinase activation by asbestos was attenuated by suramin, which inhibits growth factor receptor interactions, or tyrphostin AG 1478, a specific inhibitor of EGF receptor tyrosine kinase activity (IC50 = 3 nM). Moreover, asbestos caused autophosphorylation of the EGF receptor, an event triggering the ERK cascade. These studies are the first to establish that a MAP kinase signal transduction pathway is initiated after phosphorylation of a peptide growth factor receptor following exposure to asbestos fibers.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8968079

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  63 in total

Review 1.  The molecular basis of asbestos induced lung injury.

Authors:  D W Kamp; S A Weitzman
Journal:  Thorax       Date:  1999-07       Impact factor: 9.139

2.  Immunolocalization of caveolin-1 in rat and human mesothelium.

Authors:  Christopher J von Ruhland; Lee Campbell; Mark Gumbleton; Bharat Jasani; Geoffrey R Newman
Journal:  J Histochem Cytochem       Date:  2004-11       Impact factor: 2.479

Review 3.  Cellular and molecular parameters of mesothelioma.

Authors:  Maria E Ramos-Nino; Joseph R Testa; Deborah A Altomare; Harvey I Pass; Michele Carbone; Maurizio Bocchetta; Brooke T Mossman
Journal:  J Cell Biochem       Date:  2006-07-01       Impact factor: 4.429

4.  Assessment of the pathogenic potential of asbestiform vs. nonasbestiform particulates (cleavage fragments) in in vitro (cell or organ culture) models and bioassays.

Authors:  Brooke T Mossman
Journal:  Regul Toxicol Pharmacol       Date:  2007-10-11       Impact factor: 3.271

5.  A Phosphotyrosine Proteomic Screen Identifies Multiple Tyrosine Kinase Signaling Pathways Aberrantly Activated in Malignant Mesothelioma.

Authors:  Craig W Menges; Yibai Chen; Brooke T Mossman; Jonathan Chernoff; Anthony T Yeung; Joseph R Testa
Journal:  Genes Cancer       Date:  2010-05-01

6.  Role of mitogen-activated protein kinases (MAPK) in cell injury and proliferation by environmental particulates.

Authors:  Maria E Ramos-Nino; Astrid Haegens; Arti Shukla; Brooke T Mossman
Journal:  Mol Cell Biochem       Date:  2002 May-Jun       Impact factor: 3.396

Review 7.  Surgical biology for the clinician: peritoneal mesothelioma: current understanding and management.

Authors:  Terence C Chua; Tristan D Yan; David L Morris
Journal:  Can J Surg       Date:  2009-02       Impact factor: 2.089

8.  Orthotopic pleural mesothelioma in mice: SPECT/CT and MR imaging with HER1- and HER2-targeted radiolabeled antibodies.

Authors:  Tapan K Nayak; Marcelino Bernardo; Diane E Milenic; Peter L Choyke; Martin W Brechbiel
Journal:  Radiology       Date:  2013-01-17       Impact factor: 11.105

9.  Tumor promoter arsenite activates extracellular signal-regulated kinase through a signaling pathway mediated by epidermal growth factor receptor and Shc.

Authors:  W Chen; J L Martindale; N J Holbrook; Y Liu
Journal:  Mol Cell Biol       Date:  1998-09       Impact factor: 4.272

10.  Synergistic effect of gefitinib and rofecoxib in mesothelioma cells.

Authors:  Daniela Stoppoloni; Claudia Canino; Irene Cardillo; Alessandra Verdina; Alfonso Baldi; Ada Sacchi; Rossella Galati
Journal:  Mol Cancer       Date:  2010-02-02       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.